235 related articles for article (PubMed ID: 21216262)
1. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on the stimulation of dopamine release evoked by nicotine in the rat brain.
Tronci V; Balfour DJ
Behav Brain Res; 2011 Jun; 219(2):354-7. PubMed ID: 21216262
[TBL] [Abstract][Full Text] [Related]
2. The mGluR5 antagonist MPEP decreased nicotine self-administration in rats and mice.
Paterson NE; Semenova S; Gasparini F; Markou A
Psychopharmacology (Berl); 2003 May; 167(3):257-64. PubMed ID: 12682710
[TBL] [Abstract][Full Text] [Related]
3. Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cue- and schedule-induced reinstatement of nicotine self-administration behavior in rats.
Bespalov AY; Dravolina OA; Sukhanov I; Zakharova E; Blokhina E; Zvartau E; Danysz W; van Heeke G; Markou A
Neuropharmacology; 2005; 49 Suppl 1():167-78. PubMed ID: 16023685
[TBL] [Abstract][Full Text] [Related]
4. Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats.
D'Souza MS; Markou A
Neuropharmacology; 2011 Dec; 61(8):1399-405. PubMed ID: 21896278
[TBL] [Abstract][Full Text] [Related]
5. The effects of the mGluR5 receptor antagonist 6-methyl-2-(phenylethynyl)-pyridine (MPEP) on behavioural responses to nicotine.
Tronci V; Vronskaya S; Montgomery N; Mura D; Balfour DJ
Psychopharmacology (Berl); 2010 Jul; 211(1):33-42. PubMed ID: 20422403
[TBL] [Abstract][Full Text] [Related]
6. The mGluR5 antagonist MPEP elevates accumbal dopamine and glycine levels; interaction with strychnine-sensitive glycine receptors.
Chau P; Söderpalm B; Ericson M
Addict Biol; 2011 Oct; 16(4):591-9. PubMed ID: 21790901
[TBL] [Abstract][Full Text] [Related]
7. Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.
Liechti ME; Markou A
Eur J Pharmacol; 2007 Jan; 554(2-3):164-74. PubMed ID: 17113075
[TBL] [Abstract][Full Text] [Related]
8. Metabotropic glutamate receptor 5 activity in the nucleus accumbens is required for the maintenance of ethanol self-administration in a rat genetic model of high alcohol intake.
Besheer J; Grondin JJ; Cannady R; Sharko AC; Faccidomo S; Hodge CW
Biol Psychiatry; 2010 May; 67(9):812-22. PubMed ID: 19897175
[TBL] [Abstract][Full Text] [Related]
9. Nicotine-induced conditioned place preference in rats: sex differences and the role of mGluR5 receptors.
Yararbas G; Keser A; Kanit L; Pogun S
Neuropharmacology; 2010 Feb; 58(2):374-82. PubMed ID: 19833142
[TBL] [Abstract][Full Text] [Related]
10. The mGluR5 antagonist MPEP decreases operant ethanol self-administration during maintenance and after repeated alcohol deprivations in alcohol-preferring (P) rats.
Schroeder JP; Overstreet DH; Hodge CW
Psychopharmacology (Berl); 2005 Apr; 179(1):262-70. PubMed ID: 15717208
[TBL] [Abstract][Full Text] [Related]
11. Blockade of mGluR5 in the nucleus accumbens shell but not core attenuates heroin seeking behavior in rats.
Lou ZZ; Chen LH; Liu HF; Ruan LM; Zhou WH
Acta Pharmacol Sin; 2014 Dec; 35(12):1485-92. PubMed ID: 25399651
[TBL] [Abstract][Full Text] [Related]
12. mGluR5 antagonist-induced psychoactive properties: MTEP drug discrimination, a pharmacologically selective non-NMDA effect with apparent lack of reinforcing properties.
Swedberg MD; Ellgren M; Raboisson P
J Pharmacol Exp Ther; 2014 Apr; 349(1):155-64. PubMed ID: 24472725
[TBL] [Abstract][Full Text] [Related]
13. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates conditioned place preference induced by various addictive and non-addictive drugs in rats.
Rutten K; Van Der Kam EL; De Vry J; Bruckmann W; Tzschentke TM
Addict Biol; 2011 Jan; 16(1):108-15. PubMed ID: 20579001
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotective activity of the mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not reflect actions at mGluR5 receptors.
Lea PM; Movsesyan VA; Faden AI
Br J Pharmacol; 2005 Jun; 145(4):527-34. PubMed ID: 15821750
[TBL] [Abstract][Full Text] [Related]
15. Antagonism at metabotropic glutamate 5 receptors inhibits nicotine- and cocaine-taking behaviours and prevents nicotine-triggered relapse to nicotine-seeking.
Tessari M; Pilla M; Andreoli M; Hutcheson DM; Heidbreder CA
Eur J Pharmacol; 2004 Sep; 499(1-2):121-33. PubMed ID: 15363959
[TBL] [Abstract][Full Text] [Related]
16. mGluR5 antagonism inhibits cocaine reinforcement and relapse by elevation of extracellular glutamate in the nucleus accumbens via a CB1 receptor mechanism.
Li X; Peng XQ; Jordan CJ; Li J; Bi GH; He Y; Yang HJ; Zhang HY; Gardner EL; Xi ZX
Sci Rep; 2018 Feb; 8(1):3686. PubMed ID: 29487381
[TBL] [Abstract][Full Text] [Related]
17. Metabotropic glutamate receptor 5 (mGluR5) antagonists attenuate cocaine priming- and cue-induced reinstatement of cocaine seeking.
Kumaresan V; Yuan M; Yee J; Famous KR; Anderson SM; Schmidt HD; Pierce RC
Behav Brain Res; 2009 Sep; 202(2):238-44. PubMed ID: 19463707
[TBL] [Abstract][Full Text] [Related]
18. Nicotine potentiation of brain stimulation reward reversed by DH beta E and SCH 23390, but not by eticlopride, LY 314582 or MPEP in rats.
Harrison AA; Gasparini F; Markou A
Psychopharmacology (Berl); 2002 Feb; 160(1):56-66. PubMed ID: 11862374
[TBL] [Abstract][Full Text] [Related]
19. Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists.
Bespalov A; Dravolina O; Belozertseva I; Adamcio B; Zvartau E
Behav Pharmacol; 2006 Jun; 17(4):295-302. PubMed ID: 16914947
[TBL] [Abstract][Full Text] [Related]
20. The mGluR5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats.
Campbell UC; Lalwani K; Hernandez L; Kinney GG; Conn PJ; Bristow LJ
Psychopharmacology (Berl); 2004 Sep; 175(3):310-8. PubMed ID: 15024550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
